OncoMatch/Clinical Trials/NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Is NCT04973605 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for relapsed/refractory multiple myeloma.
Treatment: Sonrotoclax · Dexamethasone · Carfilzomib · Daratumumab · Pomalidomide — The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CCND1 t(11;14) translocation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody
Must have received: IMiD
had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody
Must have received: anti-CD38 monoclonal antibody
had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody
Cannot have received: BCL2 inhibitor (sonrotoclax, venetoclax)
Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL (transfusions permitted); Platelet count ≥ 75,000/μL independent of growth factor support and transfusions; ANC ≥ 1000/mm^3
Liver function
ALT and AST ≤ 3 x ULN and total bilirubin ≤ 2.0 x ULN (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Adequate organ function defined as: Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted); Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions; Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment; ALT and AST ≤ 3 x ULN and total bilirubin ≤ 2.0 x ULN (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama At Birmingham Hospital · Birmingham, Alabama
- City of Hope National Medical Center · Duarte, California
- City of Hope Irvine Lennar · Irvine, California
- University of California At San Francisco · San Francisco, California
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify